Latest News

Tumour-infiltrating lymphocytes (TILs) are crucial effectors of the anticancer immune response and are hypothesized to be key determinants the efficacy of immune-checkpoint inhibitors (ICIs). Herein, the authors review studies that have evaluated the roles of various TIL subsets as predictive biomarkers for ICIs, as well as opportunities, challenges and strategies for future research in this field.

Members of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center joined more than 11,000 physicians, scientists, and trainees focused on advancing research and clinical care in breast cancer attending the annual San Antonio Breast Cancer Symposium December 10-14, 2024. The Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease to an international audience of academic and private physicians and researchers.

Thazin Nwe Aung, PhD, Associate Research Scientist in Pathology, has been selected for a Patterson Mentored Research Award. Dr. Aung is a member of the Rimm Lab, and her mentor is David Rimm, MD, PhD, Anthony N. Brady Professor of Pathology and of Medicine (Medical Oncology).

Researchers developed a highly sensitive, analytic, quantitative immunofluorescence assay that may enable more patients with lung cancer to benefit from an approved targeted therapy.The test measures HER2, a commonly used biomarker for breast cancer.

A new, highly sensitive test for a cancer biomarker could allow more lung cancer patients to benefit from a recently FDA-approved chemotherapy.

Two genes could serve as a screening mechanism for resistance to immunotherapy in non-small cell lung cancer (NSCLC), though further research is needed.

A recent study conducted by scientists at Yale Cancer Center demonstrates that spatial gene signatures can significantly enhance the prediction of immunotherapy outcomes in patients with melanoma.

David Rimm, MD, PhD, Anthony N. Brady Professor of Pathology, professor, medicine, Medical Oncology, Yale School of Medicine; director, Physician Scientist Training Program, Pathology Research, director, Tissue Microarray Facility, director, Yale Pathology Tissue Services, Pathology, Yale Cancer Center, discusses the primary challenges in distinguishing between HER2-low and HER2-ultralow breast cancer using current immunohistochemistry diagnostic kits.